A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings. The new ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will receive ...
Scars are a natural part of the body’s healing process. When skin is damaged from an accident or injury, the body builds new tissue made from collagen to close those gaps, according to the Cleveland ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback